-
1.发明申请Anti-IL-20 antibodies and binding partners and methods of using in inflammation 审中-公开抗IL-20抗体和结合配偶体以及在炎症中使用的方法公开(公告)号：US20060134756A1
公开(公告)日：2006-06-22
申请号：US10807997
申请日：2004-03-24
申请人： Wenfeng Xu , Wayne Kindsvogel , Yasmin Chandrasekher , Stacey Dillon , Joyce Lehner , Anthony Siadak , Pallavur Sivakumar , Margaret Moore
发明人： Wenfeng Xu , Wayne Kindsvogel , Yasmin Chandrasekher , Stacey Dillon , Joyce Lehner , Anthony Siadak , Pallavur Sivakumar , Margaret Moore
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-20 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. The present invention includes anti-IL-20 and anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-20多肽分子的活性。 IL-20和IL-22是涉及炎症过程和人类疾病的细胞因子。 本发明包括抗IL-20和抗IL-22RA抗体和结合配偶体，以及使用这种抗体和结合配偶体拮抗IL-20的方法。
-
公开(公告)号：US20060141582A1
公开(公告)日：2006-06-29
申请号：US11256499
申请日：2005-10-21
申请人： Wenfeng Xu , Wayne Kindsvogel , Yasmin Chandrasekher , Stacey Dillon , Joyce Lehner , Anthony Siadak , Pallavur Sivakumar , Margaret Moore
发明人： Wenfeng Xu , Wayne Kindsvogel , Yasmin Chandrasekher , Stacey Dillon , Joyce Lehner , Anthony Siadak , Pallavur Sivakumar , Margaret Moore
IPC分类号： C12P21/04
CPC分类号： C07K16/244 , A61K49/0008 , A61K2039/505 , C07K16/2866 , C07K2319/30 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
-
3.发明申请Anti-IL-20 receptor antibodies and binding partners and methods of using in inflammation 审中-公开抗IL-20受体抗体和结合配偶体以及在炎症中使用的方法公开(公告)号：US20050170468A1
公开(公告)日：2005-08-04
申请号：US10994151
申请日：2004-11-19
申请人： Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven Hughes , Yasmin Chandrasekher , Stacey Dillon , Joyce Lehner , Anthony Siadak , Pallavur Sivakumar , Margaret Moore
发明人： Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven Hughes , Yasmin Chandrasekher , Stacey Dillon , Joyce Lehner , Anthony Siadak , Pallavur Sivakumar , Margaret Moore
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/20 , A61K47/60 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking the activity of IL-20 receptor polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 receptor antibodies and binding partners, including anti-IL-20RA, anti-IL-20RB and anti-IL-20RA/IL-20RB antibodies as well as methods for antagonizing IL-20RA and IL-20RB, either individually or together, using such antibodies and binding partners.
摘要翻译： 本发明涉及阻断IL-20受体多肽分子的活性。 IL-20是涉及炎症过程和人类疾病的细胞因子。 IL-20RA / IL-20RB是IL-20的常见受体。 本发明包括抗IL-20受体抗体和结合配偶体，包括抗IL-20RA，抗IL-20RB和抗IL-20RA / IL-20RB抗体以及拮抗IL-20RA和IL- 20RB，单独或一起使用这种抗体和结合配偶体。
-
4.发明申请Anti-IL-20 antibodies and binding partners and methods of using in inflammation 有权抗IL-20抗体和结合配偶体以及在炎症中使用的方法公开(公告)号：US20050136004A1
公开(公告)日：2005-06-23
申请号：US10994116
申请日：2004-11-19
申请人： Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven Hughes , Yasmin Chandrasekher , Stacey Dillon , Joyce Lehner , Anthony Siadak , Pallavur Sivakumar , Margaret Moore
发明人： Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven Hughes , Yasmin Chandrasekher , Stacey Dillon , Joyce Lehner , Anthony Siadak , Pallavur Sivakumar , Margaret Moore
IPC分类号： A61K38/00 , A61K38/20 , C07K14/54 , C07K14/715 , C07K16/24 , C07K16/28 , C12P21/04 , A61K51/00 , A61K39/395
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/20 , A61K47/60 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
摘要翻译： 本发明涉及阻断IL-20多肽分子的活性。 IL-20是涉及炎症过程和人类疾病的细胞因子。 IL-20RA / IL-20RB是IL-20的常见受体。 本发明包括抗IL-20抗体和结合配偶体，以及使用这种抗体和结合配偶体拮抗IL-20的方法。
-
公开(公告)号：US20080033148A1
公开(公告)日：2008-02-07
申请号：US11829755
申请日：2007-07-27
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/34
摘要： The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
摘要翻译： 本发明涉及阻断IL-TIF多肽分子的活性。 IL-TIF是涉及炎症过程和人类疾病的细胞因子。 本发明包括抗IL-TIF抗体和结合配偶体，以及在IL-TIF相关的人类炎性疾病中使用这样的抗体和结合伴侣拮抗IL-TIF的方法，以及其它用途。
-
6.发明申请公开(公告)号：US20070178063A1
公开(公告)日：2007-08-02
申请号：US11539511
申请日：2006-10-06
申请人： Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
发明人： Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
IPC分类号： A61K38/20 , A61K39/395
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
摘要翻译： 描述了通过用IL-21共同施用治疗性单克隆抗体来治疗癌症的方法。 可以使用的示例性单克隆抗体是利妥昔单抗，曲妥珠单抗和抗CTLA-4抗体。 联合治疗的增强的抗肿瘤剂对于单克隆治疗顽固性，用单克隆抗体治疗后复发或增强的IL-21抗肿瘤作用降低与使用单克隆抗体治疗相关的毒性的患者群体特别有用。
-
公开(公告)号：US20070173445A1
公开(公告)日：2007-07-26
申请号：US11548439
申请日：2006-10-11
IPC分类号： A61K38/20
CPC分类号： A61K47/60 , A61K38/20 , A61K38/21 , C07K14/54 , Y02A50/385 , Y02A50/393
摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
-
公开(公告)号：US20070048262A1
公开(公告)日：2007-03-01
申请号：US11531646
申请日：2006-09-13
IPC分类号： A61K38/20
CPC分类号： A61K47/60 , A61K38/20 , A61K38/21 , C07K14/54 , Y02A50/385 , Y02A50/393
摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
-
公开(公告)号：US20060024269A1
公开(公告)日：2006-02-02
申请号：US11193955
申请日：2005-07-29
申请人： Sean Doyle , Kevin Klucher , Pallavur Sivakumar , Wayne Kindsvogel , Chung Chan
发明人： Sean Doyle , Kevin Klucher , Pallavur Sivakumar , Wayne Kindsvogel , Chung Chan
CPC分类号： A61K38/20 , A61K38/21 , A61K47/60 , C07K14/54 , C07K14/715 , C07K14/7155 , A61K2300/00
摘要： Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
-
10.发明申请公开(公告)号：US20050265966A1
公开(公告)日：2005-12-01
申请号：US11134489
申请日：2005-05-20
申请人： Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
发明人： Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
IPC分类号： A61K38/20 , A61K39/395 , C07K16/28 , C07K16/32
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
摘要翻译： 描述了通过用IL-21共同施用治疗性单克隆抗体来治疗癌症的方法。 可以使用的示例性单克隆抗体是利妥昔单抗，曲妥珠单抗和抗CTLA-4抗体。 联合治疗的增强的抗肿瘤剂对于单克隆治疗顽固性，用单克隆抗体治疗后复发或增强的IL-21抗肿瘤作用降低与使用单克隆抗体治疗相关的毒性的患者群体特别有用。
-
-
-
-
-
-
-
-
-
搜索结果
115 条记录 (耗时 0.047 秒)
